Impact of early conversion from cyclosporin to everolimus on left ventricular mass index: A randomized controlled trial
This is an 18-month prospective, randomized controlled trial (RCT) designed to compare the effect of early conversion from cyclosporin to everolimus/mycophenolic acid (E-MPA) between 3 and 4 months post-transplant to cyclosporin/mycophenolic acid (CsA-MPA) on left ventricular mass index (LVMI) at 3...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
2017
|
| Online Access: | http://hdl.handle.net/20.500.11937/56971 |
| _version_ | 1848759982706655232 |
|---|---|
| author | Krishnan, A. Teixeira-Pinto, A. Chan, D. Chakera, Aron Dogra, G. Boudville, N. Irish, A. Morgan, K. Phillips, J. Wong, G. Lim, W. |
| author_facet | Krishnan, A. Teixeira-Pinto, A. Chan, D. Chakera, Aron Dogra, G. Boudville, N. Irish, A. Morgan, K. Phillips, J. Wong, G. Lim, W. |
| author_sort | Krishnan, A. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | This is an 18-month prospective, randomized controlled trial (RCT) designed to compare the effect of early conversion from cyclosporin to everolimus/mycophenolic acid (E-MPA) between 3 and 4 months post-transplant to cyclosporin/mycophenolic acid (CsA-MPA) on left ventricular mass index (LVMI) at 3 and 18 months post-transplant (primary outcome). Secondary outcomes included estimated glomerular filtration rate (eGFR), viral infection, and adverse events. Twenty-four patients were randomized in a 1:1 ratio to E-MPA or CsA-MPA groups. There were no significant differences in mean (SD) LVMI at 3 (51.6±18.5 vs 53.7±15.7 g/m 2.7 ) and 18 months (52.7±16.3 vs 51.7±16.8 g/m 2.7 ) between CsA-MPA and E-MPA groups. The incidence of viral infections was reduced in E-MPA compared to CsA-MPA treatment groups (8% vs 50%, P=.02), but the incidences of acute rejection, adverse events, and drug discontinuation were similar between groups. There was an overall increase in eGFR with time (0.04 log- mL/min/1.73 m 2 per 6 months, P=.012) but no significant difference between the two groups across time (0.11 log- mL/min/1.73 m 2 , P=.311). Immunosuppressive regimen comprising early conversion from cyclosporine to everolimus was not associated with a regression of LVMI, but a lower risk of viral infections was observed. |
| first_indexed | 2025-11-14T10:08:32Z |
| format | Journal Article |
| id | curtin-20.500.11937-56971 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T10:08:32Z |
| publishDate | 2017 |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-569712018-01-15T03:39:14Z Impact of early conversion from cyclosporin to everolimus on left ventricular mass index: A randomized controlled trial Krishnan, A. Teixeira-Pinto, A. Chan, D. Chakera, Aron Dogra, G. Boudville, N. Irish, A. Morgan, K. Phillips, J. Wong, G. Lim, W. This is an 18-month prospective, randomized controlled trial (RCT) designed to compare the effect of early conversion from cyclosporin to everolimus/mycophenolic acid (E-MPA) between 3 and 4 months post-transplant to cyclosporin/mycophenolic acid (CsA-MPA) on left ventricular mass index (LVMI) at 3 and 18 months post-transplant (primary outcome). Secondary outcomes included estimated glomerular filtration rate (eGFR), viral infection, and adverse events. Twenty-four patients were randomized in a 1:1 ratio to E-MPA or CsA-MPA groups. There were no significant differences in mean (SD) LVMI at 3 (51.6±18.5 vs 53.7±15.7 g/m 2.7 ) and 18 months (52.7±16.3 vs 51.7±16.8 g/m 2.7 ) between CsA-MPA and E-MPA groups. The incidence of viral infections was reduced in E-MPA compared to CsA-MPA treatment groups (8% vs 50%, P=.02), but the incidences of acute rejection, adverse events, and drug discontinuation were similar between groups. There was an overall increase in eGFR with time (0.04 log- mL/min/1.73 m 2 per 6 months, P=.012) but no significant difference between the two groups across time (0.11 log- mL/min/1.73 m 2 , P=.311). Immunosuppressive regimen comprising early conversion from cyclosporine to everolimus was not associated with a regression of LVMI, but a lower risk of viral infections was observed. 2017 Journal Article http://hdl.handle.net/20.500.11937/56971 10.1111/ctr.13043 restricted |
| spellingShingle | Krishnan, A. Teixeira-Pinto, A. Chan, D. Chakera, Aron Dogra, G. Boudville, N. Irish, A. Morgan, K. Phillips, J. Wong, G. Lim, W. Impact of early conversion from cyclosporin to everolimus on left ventricular mass index: A randomized controlled trial |
| title | Impact of early conversion from cyclosporin to everolimus on left ventricular mass index: A randomized controlled trial |
| title_full | Impact of early conversion from cyclosporin to everolimus on left ventricular mass index: A randomized controlled trial |
| title_fullStr | Impact of early conversion from cyclosporin to everolimus on left ventricular mass index: A randomized controlled trial |
| title_full_unstemmed | Impact of early conversion from cyclosporin to everolimus on left ventricular mass index: A randomized controlled trial |
| title_short | Impact of early conversion from cyclosporin to everolimus on left ventricular mass index: A randomized controlled trial |
| title_sort | impact of early conversion from cyclosporin to everolimus on left ventricular mass index: a randomized controlled trial |
| url | http://hdl.handle.net/20.500.11937/56971 |